最新ニュース BTC Digital (NASDAQ:BTCT) 株価情報

BTC Digital

Meten Holding Gr

BTC Digital Ltd is a crypto asset technology company based in the U.S. with a focus on bitcoin mining. The company also generates revenue through mining machine resale and rental business operations.

BTC Digital Ltd

Bitcoin - TrueUSD

RBC Capital analyst Matthew Hedberg maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Outperform and raises the price target from $328 to $358.

News

Price Target

Analyst Ratings

CYBR

RBC Capital Maintains Outperform on CyberArk Software, Raises Price Target to $358

Goldman Sachs analyst Ryan Nash maintains UWM Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) with a Neutral and lowers the price target from $8.5 to $7.5.

UWMC

Goldman Sachs Maintains Neutral on UWM Hldgs, Lowers Price Target to $7.5

General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) is recalling over 539,000 vehicles due to two separate transmission-related issues, according to the National Highway Traffic Safety Administration.
Based on information from the NHTSA, Reuters reported that one of the recalls involved 77,824 Chevrolet Express and GMC Savana models from 2022-2023 due to incorrect software in the transmission control module.
The faulty software may result in unintended vehicle movement, reduced power, sudden deceleration, or rear-wheel lockup, significantly increasing the crash risk.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/24/11/41932481/gm-unveils-2026-cadillac-vistiq-electric-suv-with-starting-price-below-tesla-model-x-lucid-gravity" rel="noreferrer noopener">GM Unveils 2026 Cadillac Vistiq Electric SUV With Starting Price Below Tesla Model X, Lucid Gravity</a>
The report noted that another recall affects 461,839 vehicles, including 2020-2022 Chevrolet Silverado, 2021 Cadillac Escalade, GMC Sierra, Chevrolet Tahoe, and GMC Yukon models, due to a faulty transmission control valve that could cause a rear-wheel lockup.
GM will provide a free software update to fix the issue and implement a special coverage program for vehicles with defective control valves. Dealers have been ordered to stop delivering the affected vehicles immediately.
In the first week of November, General Motors <a target="_blank" href="https://www.benzinga.com/news/24/11/41746228/gm-recalls-107-bolt-electric-vehicles-due-to-fire-risks" rel="noreferrer noopener">recalled 107 Chevrolet Bolt EV and EUV vehicles </a>from 2020-2022 due to fire risks, according to the NHTSA. The vehicles had previously received diagnostic software, but incorrect installation could have led to battery fires at full charge.
Price Action: GM shares traded higher by 2.44% at $59.12 at the last check Thursday.
Image via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com//node/41973501" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Profit Power Vs. Rivian&#8217;s Cash Burn: Can The Gap Be Narrowed?</a></li>
</ul>

Equities

Media

General Motors Faces Recall Crisis With Faulty Transmissions: Details

RBC Capital analyst Gregory Renza reiterates Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) with a Sector Perform and maintains $4 price target.

Reiteration

FULC

RBC Capital Reiterates Sector Perform on Fulcrum Therapeutics, Maintains $4 Price Target

Goldman Sachs analyst Eric Sheridan maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $430 to $490.

SPOT

Goldman Sachs Maintains Buy on Spotify Technology, Raises Price Target to $490

Canaccord Genuity analyst Brian McNamara maintains YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) with a Hold and maintains $44 price target.

YETI

Canaccord Genuity Maintains Hold on YETI Holdings, Maintains $44 Price Target

Goldman Sachs analyst Will Nance maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Buy and raises the price target from $106 to $119.

FOUR

Goldman Sachs Maintains Buy on Shift4 Payments, Raises Price Target to $119

RBC Capital analyst Jimmy Shan maintains Minto Apartment (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MI#TSX">MI</a>) with a Outperform and lowers the price target from C$21.5 to C$20.5.

TSX:MI

TSX:MI/UN

RBC Capital Maintains Outperform on Minto Apartment, Lowers Price Target to C$20.5

Trading Ideas

PXDT

Pixie Dust Technologies Shares Halted On Circuit Breaker To The Upside, Stock Now Up 108.9%

Goldman Sachs analyst Mike Niehuser maintains Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) with a Buy and raises the price target from $17 to $19.

Goldman Sachs Maintains Buy on Nu Holdings, Raises Price Target to $19

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and maintains $171 price target.

BNTX

Canaccord Genuity Maintains Buy on BioNTech, Maintains $171 Price Target

RBC Capital analyst Douglas Miehm reiterates Oncolytics Biotech (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ONC#TSX">ONC</a>) with a Outperform and maintains C$6 price target.

ONCY

TSX:ONC

RBC Capital Reiterates Outperform on Oncolytics Biotech, Maintains C$6 Price Target

Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) shares are trading higher by roughly 5% during November after Donald Trump's win in the <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">presidential election</a>, as investors anticipate a more favorable regulatory and economic environment for the oil and gas sector.
Trump's administration is expected to prioritize fossil fuel production, potentially reversing recent policies on environmental restrictions and supporting domestic energy expansion, which could directly benefit Exxon's extensive U.S. operations. 
Trump's stance on reducing regulations in the energy sector could make it easier and more cost-effective for Exxon to expand drilling projects, especially in U.S. shale regions like the Permian Basin, where the company has invested heavily in recent years.
Read Also: <a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a>
What To Know: One anticipated shift under Trump's policies would be a rollback of regulations tied to carbon emissions, methane leaks, and drilling permits, which had increased compliance costs for companies like Exxon. 
With eased regulatory pressures, Exxon would have greater flexibility to explore and develop new oil and gas fields without facing stringent environmental compliance costs, potentially boosting production levels and profitability. 
Additionally, Trump's proposal to withdraw from the Paris Climate Agreement and possibly undo green energy subsidies could slow the U.S. transition to renewables, extending the market dominance of traditional energy sources where Exxon is well-positioned.
Read Also: <a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a>
What Else: Trump's protectionist trade policies, particularly his advocacy for tariffs on foreign imports, could also play a role in shaping Exxon's strategy. 
While higher tariffs could increase costs for some imported materials used in refining and exploration, the overarching goal to strengthen domestic energy independence aligns with Exxon's core U.S. operations. 
Furthermore, Trump's inclination to ease sanctions on certain countries, such as Russia, could create new avenues for Exxon to partner in international projects, a potential growth area constrained by recent sanctions.
While uncertainties remain in the global oil market, Trump's commitment to bolstering fossil fuel production and easing regulatory constraints provides an optimistic outlook for Exxon's growth trajectory, making the stock an appealing choice for energy investors post-election.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41971830/producer-inflation-rises-more-than-expected-in-october-should-traders-rethink-interest-rate-cut-path">Producer Inflation Rises More Than Expected In October: Should Traders Rethink Interest Rate Cut Path?</a>
<h2 class="wp-block-heading">How To Buy XOM Stock</h2>
By now you're likely curious about how to participate in the market for Exxon Mobil &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
In the the case of Exxon Mobil, which is trading at $121.61 as of publishing time, $100 would buy you 0.82 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, XOM has a 52-week high of $126.34 and a 52-week low of $95.77.

What's Going On With Exxon Mobil (XOM) Stock?

Goldman Sachs analyst Mark Delaney maintains Luminar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAZR#NASDAQ">LAZR</a>) with a Sell and lowers the price target from $0.75 to $0.5.

LAZR

Goldman Sachs Maintains Sell on Luminar Technologies, Lowers Price Target to $0.5

Salesforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) is aggressively embracing AI in enterprise software. CEO Marc Benioff is positioning the company&#8217;s AI agents as the industry&#8217;s next significant evolution.
The company plans to deploy software bots that can handle various tasks autonomously, aiming to streamline operations and reduce the workload for human employees.
Also Read: <a target="_blank" href="https://www.benzinga.com/top-stories/24/10/41428765/microsoft-salesforce-battle-heats-up-as-ai-agent-technology-takes-center-stage" rel="noreferrer noopener">Microsoft, Salesforce Battle Heats Up As AI Agent Technology Takes Center Stage</a>
During a recent episode of the Equity podcast, Benioff shared his vision, underscoring how this shift could reshape enterprise software as we know it.
Benioff emphasized the potential of these AI agents to revolutionize productivity by extending workforce capabilities without limitations, TechCrunch <a target="_blank" href="https://techcrunch.com/podcast/marc-benioff-says-its-crazy-talk-that-ai-will-hurt-salesforce-wants-a-billion-ai-agents-in-a-year/" rel="noreferrer noopener">reports</a>.
The Salesforce chief noted that hundreds of companies already leverage <a target="_blank" href="https://www.benzinga.com/markets/equities/24/10/41607435/salesforce-launches-agentforce-redefining-ai-in-business-with-autonomous-solutions" rel="noreferrer noopener">the Agentforce platform</a>, an AI-driven tool enabling autonomous task execution across business functions.
He set an ambitious target of deploying a billion AI agents within a year, showcasing this technology&#8217;s scalability and market demand.
Benioff shared a personal example from a recent visit to a Disney park, using the company&#8217;s virtual tour guide feature. The AI agent analyzed historical ride preferences and current park traffic, suggesting customized itineraries.
This personalized approach demonstrated how AI can enhance user experiences across different sectors, including entertainment, retail, and healthcare.
While Salesforce continues to develop its Agentforce platform, Benioff criticized Microsoft Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) AI offerings and expressed skepticism about Microsoft&#8217;s Copilot agents. He cited user complaints and research indicating security and functionality issues with Microsoft&#8217;s solutions.
Despite the rise of new AI-focused startups, Benioff remains confident in Salesforce&#8217;s position.
Benioff emphasized that Salesforce&#8217;s secure data infrastructure sets it apart, enabling more reliable AI-driven insights and services.
As part of its growth strategy, Salesforce uses its own AI agents internally across various departments, including customer service and sales.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14093208/newplot-8.png" alt="" class="wp-image-648092" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14093208/newplot-8.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/14093208/newplot-8-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Northland Capital Partners said Salesforce&#8217;s AgentForce platform <a target="_blank" href="https://www.benzinga.com/top-stories/24/10/41145130/salesforces-genai-platform-agentforce-on-par-with-microsoft-analyst" rel="noreferrer noopener">is &#8220;on par&#8221; with</a> Microsoft.
Jim Cramer, host of CNBC&#8217;s &#8220;Mad Money,&#8221; praised Salesforce for its <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41890694/jim-cramer-says-salesforce-agentforce-is-the-best-use-of-ai-he-has-seen-makes-sense-that-the-stock-has-gone-up-so-much" rel="noreferrer noopener">innovative AI product</a>, Agentforce, crediting the tool for driving the recent surge in the company&#8217;s stock.
Cramer shared his views on X, describing Agentforce as &#8220;pretty revolutionary.&#8221; He pointed out that the stock&#8217;s upward movement aligns with the impact of this cutting-edge AI solution and highlighted it as the most effective AI use case he has seen, validating the stock&#8217;s rally.
Salesforce&nbsp;stock surged over 33% year-to-date. Investors can gain exposure to the stock through SPDR Select Sector Fund &#8211; Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) and Vanguard Total Stock Market ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTI#NYSE">VTI</a>).
Price Action: CRM stock is down 2.18% at $334.28 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/41971559/disneys-q4-boosted-by-streaming-gains-strong-box-office-and-solid-parks-performance" target="_blank" rel="noreferrer noopener">Disney Q4 Earnings: Revenue And Profit Beat, Best Film Studio Performance, 3-Year Outlook And More</a></li>
</ul>
Photo by NYCStock via Shutterstock

Management

Tech

MSFT

Salesforce CEO Marc Benioff Bets Big on Billion Bots

Canaccord Genuity analyst Sumant Kulkarni maintains Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) with a Buy and lowers the price target from $25 to $23.

ZVRA

Canaccord Genuity Maintains Buy on Zevra Therapeutics, Lowers Price Target to $23

RBC Capital analyst Michael Harvey reiterates Peyto Exploration &amp; Dev (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PEY#TSX">PEY</a>) with a Sector Perform and maintains C$17 price target.

TSX:PEY

RBC Capital Reiterates Sector Perform on Peyto Exploration & Dev, Maintains C$17 Price Target

Goldman Sachs analyst Ryan Nash maintains loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) with a Sell and raises the price target from $1.7 to $2.7.

Goldman Sachs Maintains Sell on loanDepot, Raises Price Target to $2.7

On Thursday, Immutep Limited&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41970785/immuteps-efti-shows-excellent-survival-data-from-insight-003-trial-in-non-small-cell-lung-cancer" rel="noreferrer noopener">cancer (1L NSCLC) patients</a>.
The survival data as of data cutoff of Oct. 15 from the triple combination therapy in patients irrespective of PD-L1 expression with a minimum followup of 22 months (N=21) shows:
<ul>
<li>Median Overall Survival (OS) of 32.9 months.</li>
<li>Median Progression-Free Survival (PFS) of 12.7 months.</li>
<li>24-month Overall Survival (OS) of 81.0%.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39747049/australia-based-cancer-focused-immuteps-lead-cancer-drug-shows-meaningful-response-in-untreated-h" rel="noreferrer noopener">Australia Based Cancer Focused Immutep&#8217;s Lead Cancer Drug Shows &#8216;Meaningful Response&#8217; In Untreated Head &amp; Neck Cancer, Stock Soars</a>
The company compares the data with the 22.0-month median OS, 9.0-month median PFS, and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in non-squamous 1L NSCLC regardless of PD-L1 expression.
Marc Voigt, CEO of Immutep, said, &#8220;The overall survival and progression-free survival data from this mature cohort of patients in INSIGHT-003 with nearly a 2-year minimum followup exceeds our expectations.&#8221;
Data from all evaluable patients to date (N=40) demonstrates significant improvement in Overall Response Rate (ORR) across all levels of PD-L1 expression compared to historical control:
<ul>
<li>75.0% ORR versus 62.1% ORR in patients with high PD-L1 expression.</li>
<li>58.8% ORR versus 49.2% ORR in patients with low PD-L1 expression.</li>
<li>47.4% ORR versus 32.3% ORR in patients with negative PD-L1.</li>
<li>In this all-comer PD-L1 trial, the 55.0% ORR and 87.5% Disease Control Rate (DCR) are from the following breakdown of patients by PD-L1 expression: high PD-L1 expression (N=4), low PD-L1 expression (N=17), and negative PD-L1 (N=19).</li>
<li>Compared to the general 1L NSCLC patient population, each of these PD-L1 levels represents roughly one-third, INSIGHT-003 is biased towards low and negative PD-L1 patients who are typically less responsive to anti-PD-1 therapy.</li>
<li>In these patients with low and negative PD-L1 expression (36 of 40 patients), the triple combination achieved a 52.8% ORR and 86.1% DCR.</li>
</ul>
INSIGHT-003, a multi-centre study led by the Frankfurt Institute of Clinical Cancer Research IKF, is nearing completion of patient enrolment.
Additional data updates from this trial are expected in 2025 and beyond.
Price Action: IMMP stock is up 9.6% at $2.05 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41970133/exclusive-adial-pharmaceuticals-reveals-topline-results-from-pharmacokinetics-study-of-ad04-for-alcohol-use-disorder" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Movers

General

IMMP

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Whales with a lot of money to spend have taken a noticeably bearish stance on Shopify.
Looking at options history for Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) we detected 42 trades.
If we consider the specifics of each trade, it is accurate to state that 26% of the investors opened trades with bullish expectations and 52% with bearish.
From the overall spotted trades, 9 are puts, for a total amount of $691,916 and 33, calls, for a total amount of $5,852,437.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $40.0 to $120.0 for Shopify over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Shopify's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Shopify's whale trades within a strike price range from $40.0 to $120.0 in the last 30 days. 
<h3>Shopify 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731600949_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$29.4</td>
<td>$28.8</td>
<td>$29.04</td>
<td>$90.00</td>
<td>$1.1M</td>
<td>4.3K</td>
<td>2.0K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$22.7</td>
<td>$22.0</td>
<td>$22.7</td>
<td>$115.00</td>
<td>$1.1M</td>
<td>2.2K</td>
<td>1.8K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$22.6</td>
<td>$22.4</td>
<td>$22.4</td>
<td>$115.00</td>
<td>$672.0K</td>
<td>2.2K</td>
<td>1.8K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$15.9</td>
<td>$15.15</td>
<td>$15.54</td>
<td>$115.00</td>
<td>$634.6K</td>
<td>6.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>SHOP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$15.55</td>
<td>$15.15</td>
<td>$15.48</td>
<td>$115.00</td>
<td>$485.3K</td>
<td>6.0K</td>
<td>2.0K</td>
</tr>
</tbody>
</table>

<h3>About Shopify</h3>
Shopify offers an e-commerce platform primarily to small and medium-size businesses. The firm has two segments. The subscription solutions segment allows Shopify merchants to conduct e-commerce on a variety of platforms, including the company's website, physical stores, pop-up stores, kiosks, social networks (Facebook), and Amazon. The merchant solutions segment offers add-on products for the platform that facilitate e-commerce and include Shopify Payments, Shopify Shipping, and Shopify Capital.
In light of the recent options history for Shopify, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Shopify Standing Right Now?</h3>
<ul>
<li>With a trading volume of 5,624,338, the price of SHOP is down by -4.56%, reaching $109.84.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 89 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Shopify</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $112.4.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on Shopify with a target price of $130. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Shopify, targeting a price of $93. 
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Shopify with a target price of $94. 
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Shopify with a target price of $125. 
&#x2A; Consistent in their evaluation, an analyst from JMP Securities keeps a Market Outperform rating on Shopify with a target price of $120. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Shopify options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

SHOP

Shopify Unusual Options Activity

SNDL, LWAY, AACG among consumer staples movers

These Consumer Defensive stocks are trading higher:-Leafly Holdings Inc (LFLY) stock is trading at $3.32, a gain of $0.44, or 20.33%, on high volume.  Leafly Hldgs Inc gets a Sentiment Score of Neutral from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $60.00. Leafly

Consumer Defensive Stocks Moving Up and Down Friday: LFLY, LWAY, BTCT, VFF, ISPR, YI, BIMI, HPCO

Hims & Hers Health and BTC Digital among Consumer Staples movers

BTC Digital to buy Arkansas-Based Mining Facility

Warning: BTCT is at high risk of performing badly

BTC Digital (BTCT) announced that the company has signed a Bitcoin ($BTC) miner equipment hosting agreement with Recte Technologies, a digital asse...

BTC Digital signs agreement with Recte Technologies

09:35 EST BTC Digital (BTCT) Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...

BTC Digital Ltd trading resumes

09:30 EST BTC Digital (BTCT) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-mov...

BTC Digital Ltd trading halted, volatility trading pause

10:07 EST BTC Digital (BTCT) Ltd trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...

10:02 EST BTC Digital (BTCT) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-mov...

Comments

BTC Digital

ニュース

最新ニュース BTC Digital (NASDAQ:BTCT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル